Advances in systemic therapy of small cell cancer of the lung

Gregory A. Daniels, Alex A. Adjei

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Over the last 20 years, progress in the therapy of small cell lung cancer has been painfully slow. Despite dramatic initial responses to chemotherapy, most patients relapse quickly with an overall 5-year survival of about 5%. Recent trials however offer some hope at changing this picture. Combining standard regimens with newer agents has doubled median survival in some cases. The use of novel targeted agents holds the promise of significantly increasing the survival in this disease, with manageable toxicity. This review outlines current treatment strategies, summarizes recent clinical trials and offers a view of what the next 5 years may hold for the treatment of small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)211-221
Number of pages11
JournalExpert review of anticancer therapy
Issue number2
StatePublished - 2001


  • Gemcitabine
  • Irinotecan
  • Paclitaxel
  • Small cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Advances in systemic therapy of small cell cancer of the lung'. Together they form a unique fingerprint.

Cite this